• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury.

作者信息

Mullane K

机构信息

Gensia Pharmaceuticals Inc, San Diego, CA 92121-1207.

出版信息

Cardiovasc Res. 1993 Jan;27(1):43-7. doi: 10.1093/cvr/27.1.43.

DOI:10.1093/cvr/27.1.43
PMID:8458030
Abstract

Acadesine is the prototype of a new class of therapeutic compounds termed adenosine regulating agents. Acadesine is pharmacologically silent in normal circumstances, but its activity becomes operative during situations of net ATP catabolism, when it increases local adenosine levels. Thus acadesine is able to harness the beneficial effects of this protective autacoid without the limiting side effects associated with using adenosine itself or an adenosine mimetic or transport inhibitor. The demonstrated efficacy of acadesine in various models of myocardial ischaemia and the preliminary clinical results 48 indicate that acadesine and other ARAs could represent important new additions to the cardiologist's armamentarium to combat myocardial ischaemia and its sequelae.

摘要

相似文献

1
Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury.
Cardiovasc Res. 1993 Jan;27(1):43-7. doi: 10.1093/cvr/27.1.43.
2
Acadesine: a unique cardioprotective agent for myocardial ischemia.阿卡地辛:一种用于心肌缺血的独特心脏保护剂。
Heart Dis. 1999 Sep-Oct;1(4):255-60.
3
Acadesine, an adenosine-regulating agent with the potential for widespread indications.阿卡地辛,一种具有广泛适应症潜力的腺苷调节剂。
Expert Opin Pharmacother. 2008 Aug;9(12):2137-44. doi: 10.1517/14656566.9.12.2137.
4
Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine.再灌注后心肌梗死:使用阿卡地新调节腺苷以改善长期生存率
J Am Coll Cardiol. 2006 Jul 4;48(1):206-14. doi: 10.1016/j.jacc.2006.04.044. Epub 2006 May 11.
5
Acadesine extends the window of protection afforded by ischaemic preconditioning in conscious rabbits.阿卡地新可延长清醒家兔缺血预处理所提供的保护时限。
Cardiovasc Res. 1995 May;29(5):653-7.
6
Acadesine reduces myocardial infarct size by an adenosine mediated mechanism.
Cardiovasc Res. 1995 Apr;29(4):495-505.
7
Acadesine improves surgical myocardial protection with blood cardioplegia in ischemically injured canine hearts.
Circulation. 1993 Nov;88(5 Pt 2):II350-8.
8
Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury.通过5'-氨基咪唑-4-甲酰胺核苷增加缺血心肌血液中的腺苷浓度。对血流、粒细胞和损伤的影响。
Circulation. 1989 Nov;80(5):1400-11. doi: 10.1161/01.cir.80.5.1400.
9
Harnessing nature's own cardiac defense mechanism with acadesine, an adenosine regulating agent: importance of the endothelium.利用腺苷调节剂阿卡地辛激活机体自身的心脏防御机制:内皮的重要性
J Card Surg. 1994 May;9(3 Suppl):482-92. doi: 10.1111/jocs.1994.9.3s.482.
10
Protection against injury during ischemia and reperfusion by acadesine derivatives GP-1-468 and GP-1-668. Studies in the transplanted rat heart.阿卡地新衍生物GP-1-468和GP-1-668对缺血再灌注损伤的保护作用。对移植大鼠心脏的研究。
J Thorac Cardiovasc Surg. 1995 Sep;110(3):752-61. doi: 10.1016/S0022-5223(95)70108-7.

引用本文的文献

1
Multifaceted role of ferroptosis in cardiovascular disease.铁死亡在心血管疾病中的多效性作用。
Acta Biochim Biophys Sin (Shanghai). 2023 Feb 25;55(2):183-193. doi: 10.3724/abbs.2023019.
2
AICAR promotes endothelium-independent vasorelaxation by activating AMP-activated protein kinase via increased ZMP and decreased ATP/ADP ratio in aortic smooth muscle.AICAR 通过增加 ZMP 和降低主动脉平滑肌中的 ATP/ADP 比值,激活 AMP 激活的蛋白激酶,促进内皮依赖性血管舒张。
J Basic Clin Physiol Pharmacol. 2022 May 4;33(6):759-768. doi: 10.1515/jbcpp-2021-0308. eCollection 2022 Nov 1.
3
Adenosine kinase: A key regulator of purinergic physiology.
腺苷激酶:嘌呤能生理学的关键调节因子。
Biochem Pharmacol. 2021 May;187:114321. doi: 10.1016/j.bcp.2020.114321. Epub 2020 Nov 6.
4
The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity.AMPK 激活在阿霉素诱导的心脏毒性中的心脏保护作用。
Cardiovasc Drugs Ther. 2020 Apr;34(2):255-269. doi: 10.1007/s10557-020-06941-x.
5
Mitochondrial Genetic Disorders: Cell Signaling and Pharmacological Therapies.线粒体遗传疾病:细胞信号与药物治疗。
Cells. 2019 Mar 28;8(4):289. doi: 10.3390/cells8040289.
6
Energy disruptors: rising stars in anticancer therapy?能量干扰剂:抗癌治疗中的后起之秀?
Oncogenesis. 2016 Jan 18;5(1):e188. doi: 10.1038/oncsis.2015.46.
7
Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?你一直想了解但却不敢问的关于磷酸二酯酶5抑制剂与心脏的一切:它们是如何起作用的?
J Endocrinol Invest. 2016 Feb;39(2):131-42. doi: 10.1007/s40618-015-0339-y. Epub 2015 Jul 5.
8
AMPK activation: a therapeutic target for type 2 diabetes?AMPK 的激活:2 型糖尿病的治疗靶点?
Diabetes Metab Syndr Obes. 2014 Jun 24;7:241-53. doi: 10.2147/DMSO.S43731. eCollection 2014.
9
5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl 5'-Monophosphate (AICAR), a Highly Conserved Purine Intermediate with Multiple Effects.5-氨基咪唑-4-甲酰胺-1-β-D-呋喃核糖基5'-单磷酸(AICAR),一种具有多种作用的高度保守的嘌呤中间体。
Metabolites. 2012 Mar 23;2(2):292-302. doi: 10.3390/metabo2020292.
10
Pathophysiology of coronary collaterals.冠状动脉侧支循环的病理生理学
Curr Cardiol Rev. 2014 Feb;10(1):38-56. doi: 10.2174/1573403x113099990005.